Reductions in Corticosteroid Use in Patients with Ulcerative Colitis or Crohnʼs Disease Treated with Vedolizumab
Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Brian G. Feagan(Western University), Stephen B. Hanauer(Northwestern University), María T. Abreu(Icahn School of Medicine at Mount Sinai), Vineet Ahuja(All India Institute of Medical Sciences), Silvio Danese(IRCCS Ospedale San Raffaele), Terry Ponich(London Health Sciences Centre), Serap Sankoh(Millennium Engineering and Integration (United States)), Michael Smyth, Jean–Frédéric Colombel(Icahn School of Medicine at Mount Sinai), Irving H. Fox(Takeda (United States)), Brihad Abhyankar(Takeda (United Kingdom)), Ida Hilmi(University of Malaya)
Cited by 6
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k